C 1027

Drug Profile

C 1027

Alternative Names: C 1027 chromophore; Lidamycin

Latest Information Update: 24 Apr 2007

Price : $50

At a glance

  • Originator Taiho Pharmaceutical
  • Developer Chinese Academy of Medical Sciences; Taiho Pharmaceutical
  • Class Amino acids; Cytostatic antibiotics
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 24 Nov 2000 Phase-II clinical trials for Cancer in Japan (Unknown route)
  • 24 Nov 2000 Phase-II clinical trials for Cancer in China (Unknown route)
  • 23 Feb 2000 Profile reviewed, but no significant changes made
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top